Fundamentals of cancer metabolism
Open accessThe DOI matches its Crossref record; 203 of the 204 references it cites were found in a registry or an index.
Abstract
Tumors reprogram pathways of nutrient acquisition and metabolism to meet the bioenergetic, biosynthetic, and redox demands of malignant cells. These reprogrammed activities are now recognized as hallmarks of cancer, and recent work has uncovered remarkable flexibility in the specific pathways activated by tumor cells to support these key functions. In this perspective, we provide a conceptual framework to understand how and why metabolic reprogramming occurs in tumor cells, and the mechanisms linking altered metabolism to tumorigenesis and metastasis. Understanding these concepts will progressively support the development of new strategies to treat human cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IDH1/2 mutations have been identified in a range of tumor types, including solid tumors (e.g., gliomas and chondrosarcomas) and blood cancers like acute myelogenous leukemia (169, 170, 171).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [169]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“we propose that pharmacological ascorbate can potentially circumvent this problem by exploring two common features of cancer cells: their increased levels of labile transition metals, especially iron21, and their increased reliance on glucose uptake and glycolysis22.”
From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [22]
The cited source says what the claim attributes to it.
In the citing paper
“Alternatively, certain cancer cells may use carbon sources such as glutamine or acetate to compensate for the reduction in acetyl-CoA synthesis from glucose [94,95].”
From HIF-1-Independent Mechanisms Regulating Metabolic Adaptation in Hypoxic Cancer Cells (2021) · cites this paper as [95]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Increased aerobic glycolysis is frequently observed in BAP1+/− cells [141], also analyzing the plasmatic metabolic profiles of individuals carrying different germline BAP1 mutations in comparison to BAP1 wild-type (BAP1WT) controls derived from two families [140].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [141]
Experimental — accuracy not yet measuredIn the citing paper
“Tumour cells exhibit a high rate of glycolysis, even in conditions with ample oxygen — a phenomenon that was first described by Otto Warburg, nearly a century ago22.”
From Targeting cancer vulnerabilities with high-dose vitamin C (2019) · cites this paper as [22]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 21×
“When tumor cells become nutrient-deprived, they adapt to the microenvironment by decreasing their demand for ATP.”
BackgroundInfluentialmTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509 · cited 2×
“mTORC1 is stimulated by the presence of amino acids and activates protein synthesis via its effects on translation and ribosome biogenesis (80).”
BackgroundHow mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207 · cited 1×
“ROS are intracellular chemical species that contain oxygen and include the superoxide anion (O2 ), hydrogen peroxide (H2O2), and the hydroxyl radical (OH·) (114).”
BackgroundThe emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926 · cited 2×
“Because some altered metabolic features are observed quite generally across many types of cancer cells, reprogrammed metabolism is considered a hallmark of cancer (1, 2).”
BackgroundIDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15593 · Cited by 4,794
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver
Horton, J. D., Goldstein, J. L., & Brown, M. S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215593 · Cited by 4,092
Hypoxia-inducible factors in physiology and medicine
Semenza, G. L. (2012) · Cell · doi:10.1016/j.cell.2012.01.021 · Cited by 3,645 · cited 1×
“Themetabolic adaptation to hypoxia is coordinated by HIF-1, which induces metabolic genes involved in increasing glycolytic flux (23).”
Background
Cited by
Items 301–400 of 1,007
Shiau, J., Chuang, Y.-T., Cheng, Y., Tang, J., Hou, M., Yen, C., & Chang, H. (2022) · Antioxidants · doi:10.3390/antiox11050911 · Cited by 114
Saha, S. K., Islam, S. M. R., Abdullah-Al-Wadud, M., Islam, M. S., Ali, F., & Park, K. S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8030355 · Cited by 102
“These alterations in cellular metabolism pathways are collectively called cancer metabolism and support the acquisition and maintenance of the malignant properties of cancer cells [3].”
BackgroundSmall‐Molecule Inhibition of Glucose Transporters GLUT‐1–4
Reckzeh, E. S., & Waldmann, H. (2019) · ChemBioChem · doi:10.1002/cbic.201900544 · Cited by 112
Fatty acid synthase (FASN) regulates the mitochondrial priming of cancer cells
Schroeder, B., Steen, T. V., Espinoza, I. C., Venkatapoorna, C. M. K., Hu, Z., Martín, F., Regan, K. M., Cuyàs, E., Meng, X. W., Verdura, S., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04262-x · Cited by 121
Plasma sample based analysis of gastric cancer progression using targeted metabolomics
Lario, S., Ramírez‐Lázaro, M. J., Sanjuan-Herráez, J. D., Brunet‐Vega, A., Pericay, C., Gombau, L., Junquera, F., Quintás‐Cardama, A., & Calvet, X. (2017) · Scientific Reports · doi:10.1038/s41598-017-17921-x · Cited by 102
Defining a metabolic landscape of tumours: genome meets metabolism
Nanda, C. S., Venkateswaran, S. V., Patani, N., & Yuneva, M. O. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0663-7 · Cited by 106
Zhang, Y., Xu, Y., Lu, W., Ghergurovich, J. M., Guo, L., Blair, I. A., Rabinowitz, J. D., & Yang, X. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2020.10.002 · Cited by 96
“A widespread trait of tumor cells, which is brought about directly or indirectly by oncogenic mutations, is the reprogramming of cellular metabolism (Cairns et al., 2011; DeBerardinis and Chandel, 2016; Pavlova and Thompson, 2016; Vander Heiden et al., 2009; Vander Heiden and DeBerardinis, 2017; Zhu and Thompson, 2019…”
BackgroundMalic enzyme 2 connects the Krebs cycle intermediate fumarate to mitochondrial biogenesis
Wang, Y.-P., Sharda, A., Xu, S., van Gastel, N., Man, C. H., Choi, U., Leong, W. Z., Li, X., & Scadden, D. T. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.03.003 · Cited by 101
Liu, X., Mei, W., Padmanaban, V., Alwaseem, H., Molina, H., Passarelli, M. C., Tavora, B., & Tavazoie, S. F. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.05.008 · Cited by 106
Huang, M., Myers, C. R., Wang, Y., & You, M. (2020) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-20-0425 · Cited by 107
“While glycolysis plays an important role in tumorigenesis, mitochondria provide ATP and building blocks (for pyrimidine, amino acid, and heme biosynthesis) for cancer cells (5), increasing evidence supports a pivotal role for mitochondrial function in cancer viability.”
BackgroundEgnatchik, R. A., Brittain, E. L., Shah, A. T., Fares, W. H., Ford, H. J., Monahan, K., Kang, C., Kocurek, E. G., Shijun, Z., Luong, T., et al. (2017) · Pulmonary Circulation · doi:10.1086/690236 · Cited by 97
LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response
Ha, J. H., Radhakrishnan, R., Jayaraman, M., Yan, M., Ward, J. D., Fung, K., Moxley, K. M., Sood, A. K., Isidoro, C., Mukherjee, P., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1624 · Cited by 99
STIM1 is a metabolic checkpoint regulating the invasion and metastasis of hepatocellular carcinoma
Zhao, H., Yan, G., Zheng, L., Zhou, Y. J., Sheng, H., Wu, L., Zhang, Q., Lei, J., Zhang, J., Xin, R., et al. (2020) · Theranostics · doi:10.7150/thno.44025 · Cited by 97
“Metabolic reprogramming is fundamental for orchestrating the proliferation and metastasis of tumor cells [32-35].”
BackgroundFibrometabolism—An emerging therapeutic frontier in pulmonary fibrosis
Selvarajah, B., Azuelos, I., Anastasiou, D., & Chambers, R. C. (2021) · Science Signaling · doi:10.1126/scisignal.aay1027 · Cited by 104
“However, this hypothesis has now been largely refuted based on the evidence that cancer cells have intact mitochondrial function and generate ATP from both glycolysis and OXPHOS, with the majority coming from the latter (23).”
BackgroundPGC1α: Friend or Foe in Cancer?
Mastropasqua, F., Girolimetti, G., & Shoshan, M. C. (2018) · Genes · doi:10.3390/genes9010048 · Cited by 102
“high mitochondrial content and activity [55,56] and suggest that PGC1α expression would be high in cancer.”
BackgroundExploiting Mitochondrial Vulnerabilities to Trigger Apoptosis Selectively in Cancer Cells
Nguyen, C. C., & Pandey, S. (2019) · Cancers · doi:10.3390/cancers11070916 · Cited by 103
“They are able to manipulate metabolic and immunogenic pathways to adapt and operate under difficult conditions [3].”
BackgroundGeng, P., Qin, W., & Xu, G. (2021) · Amino Acids · doi:10.1007/s00726-021-03060-1 · Cited by 99
Kurth, I., Yamaguchi, N., Andreu-Agulló, C., Tian, H. S., Sridhar, S., Takeda, S., Gonsalves, F. C., Loo, J. M., Barlas, A., Manova-Todorova, K. O., et al. (2021) · Science Advances · doi:10.1126/sciadv.abi7511 · Cited by 99
“The search for such metabolic dependencies is an active area of cancer research (13, 14).”
Janczur Velloso, F., Filipini Rodrigues Bianco, A., Farias, J., Torres, N., Ferruzo, P., Anschau, V., Jesus-Ferreira, H. C., Chang, T., Sogayar, M., Zerbini, L., et al. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s142154 · Cited by 91
Koch, K., Hartmann, R., Tsiampali, J., Uhlmann, C., Nickel, A., He, X., Kamp, M. A., Sabel, M., Barker, R. A., Steiger, H., et al. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-0258-3 · Cited by 91
Hulea, L., Gravel, S.-P., Morita, M., Cargnello, M., Uchenunu, O., Im, Y. K., Lehuédé, C., Ma, E. H., Leibovitch, M., McLaughlan, S., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.09.001 · Cited by 91
“PHGDHandPSAT1 are overexpressed in subtypes of breast cancer, melanoma, cervical cancer, and glioma (DeBerardinis and Chandel, 2016) and are linked to poor prognosis in lung cancers (DeNicola et al.”
BackgroundInfluentialMetal-Phenolic Nanomedicines Regulate T-Cell Antitumor Function for Sono-Metabolic Cancer Therapy
Yan, J., Li, W., Tian, H., Li, B., Yu, X., Wang, G., Sang, W., & Dai, Y. (2023) · ACS Nano · doi:10.1021/acsnano.3c02428 · Cited by 96
Recent advances in the mechanism of selenoamino acids toxicity in eukaryotic cells
Lazard, M., Dauplais, M., Blanquet, S., & Plateau, P. (2017) · BioMolecular Concepts · doi:10.1515/bmc-2017-0007 · Cited by 97
“Indeed, tumor cells have a high demand for amino acids and in particular for methionine, to sustain their high proliferation rates (154).”
BackgroundMetabolic requirements of pulmonary fibrosis: role of fibroblast metabolism
Hamanaka, R. B., & Mutlu, G. M. (2021) · FEBS Journal · doi:10.1111/febs.15693 · Cited by 103
KDM6B-mediated histone demethylation of LDHA promotes lung metastasis of osteosarcoma
Jiang, Y., Li, F., Gao, B., Ma, M., Chen, M., Wu, Y., Zhang, W., Sun, Y., Liu, S., & Shen, H. (2021) · Theranostics · doi:10.7150/thno.53347 · Cited by 98
“Malignant tumors are not only genetic diseases, but also energy metabolism diseases [21].”
BackgroundADHFE1 is a breast cancer oncogene and induces metabolic reprogramming
Mishra, P., Tang, W., Putluri, V., Dorsey, T. H., Jin, F., Wang, F., Zhu, D., Amable, L., Deng, T., Zhang, S., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci93815 · Cited by 90
“This reprogramming leads to increased availability of putative oncogenic metabolites that are used for the synthesis of biomolecules, energy metabolism, or as signaling molecules (3, 4).”
BackgroundDaemen, A., Liu, B., Song, K., Kwong, M., Gao, M., Hong, R., Nannini, M., Peterson, D., Liederer, B. M., de la Cruz, C., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.06.003 · Cited by 88
Román, M. S., & Wagner, A. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006340 · Cited by 99
“For example, they may help explain a hallmark of cancer, the metabolic heterogeneity within tumors [78].”
BackgroundOliynyk, G., Ruiz-Pérez, M. V., Sainero‐Alcolado, L., Dzieran, J., Zirath, H., Gallart‐Ayala, H., Wheelock, C. E., Johansson, H. J., Nilsson, R., Lehtiö, J., et al. (2019) · iScience · doi:10.1016/j.isci.2019.10.020 · Cited by 98
MicroRNAs in Tumor Cell Metabolism: Roles and Therapeutic Opportunities
Pedroza‐Torres, A., Romero-Cordoba, S. L., Justo-Garrido, M., Salido-Guadarrama, I., Rodríguez‐Bautista, R., Montaño, S., Muñiz-Mendoza, R., Arriaga-Canon, C., Fragoso‐Ontiveros, V., Álvarez-Gómez, R. M., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01404 · Cited by 97
Targeting cancer-cell mitochondria and metabolism to improve radiotherapy response
McCann, E., O'Sullivan, J. N., & Marcone, S. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100905 · Cited by 93
Chicco, A. J., Le, C. H., Gnaiger, E., Dreyer, H. C., Muyskens, J. B., D’Alessandro, A., Nemkov, T. G., Hocker, A. D., Prenni, J. E., Wolfe, L. M., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000470 · Cited by 98
“These findings bear a striking resemblance to emerging perspectives on cancer metabolism, where a similarly integrated view of metabolic adaptation has begun to transcend the classic Warburg hypothesis (77).”
ResultSies, H. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813146-6.00013-8 · Cited by 112
Programmable ROS‐Mediated Cancer Therapy via Magneto‐Inductions
Wu, J., Ning, P., Gao, R., Feng, Q., Shen, Y., Zhang, Y., Li, Y., Xu, C., Qin, Y., Plaza, G. R., et al. (2020) · Advanced Science · doi:10.1002/advs.201902933 · Cited by 89
How Comorbidities Shape Cancer Biology and Survival
Panigrahi, G., & Ambs, S. (2021) · Trends in cancer · doi:10.1016/j.trecan.2020.12.010 · Cited by 97
Targetome analysis of chaperone-mediated autophagy in cancer cells
Hao, Y., Kacal, M., Ouchida, A. T., Zhang, B., Norberg, E., & Vakifahmetoglu-Norberg, H. (2019) · Autophagy · doi:10.1080/15548627.2019.1586255 · Cited by 87
“Nutrient limitation can slowdown, alter or even completely downregulate various metabolic pathways to adjust to scarce conditions [30,31].”
BackgroundCretella, D., Fumarola, C., Bonelli, M. A., Alfieri, R. R., Monica, S. L., Digiacomo, G., Cavazzoni, A., Galetti, M., Generali, D., & Petronini, P. G. (2019) · Scientific Reports · doi:10.1038/s41598-019-49484-4 · Cited by 88
Li, Y., Kasim, V., Yan, X., Li, L., Meliala, I. T. S., Huang, C., Li, Z., Lei, K., Song, G., Zheng, X., et al. (2019) · Theranostics · doi:10.7150/thno.34931 · Cited by 97
“Metabolic reprogramming is a characteristic of tumor cells and is closely related to malignancy [1, 2].”
BackgroundTargeting extracellular nutrient dependencies of cancer cells
García‐Bermúdez, J., Williams, R. T., Guarecuco, R., & Birsoy, K. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.11.011 · Cited by 98
“Metabolic plasticity is particularly important for cancer cells as they experience nutrient and oxygen deprivation in the tumor microenvironment due to a dysfunctional vasculature and high nutrient consumption rates [1].”
BackgroundGlutamine Synthetase as a Therapeutic Target for Cancer Treatment
Kim, G. W., Lee, D. H., Jeon, Y. H., Yoo, J. H., Kim, S. Y., Lee, S. W., Cho, H. Y., & Kwon, S. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041701 · Cited by 104
“Cancer cells rewire metabolism to facilitate rapid proliferation and maintain survival under harsh conditions, such as nutrient-deprived and poorly vascularized environments (Figure 1) [6,7].”
BackgroundCharacterization of the fatty acid metabolism in colorectal cancer to guide clinical therapy
Ding, C., Shan, Z., Li, M., Chen, H., Li, X., & Jin, Z. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.02.010 · Cited by 109
“Cell metabolic activity changes are cancer hallmarks.(22) For instance, the upregulated glycolytic metabolism is one of the physiological characteristics of human malignant tumor.”
BackgroundThe Intersection of Purine and Mitochondrial Metabolism in Cancer
Vitto, H. D., Arachchige, D., Richardson, B. C., & French, J. B. (2021) · Cells · doi:10.3390/cells10102603 · Cited by 95
“The first historical evidence that cancer cells adapt their metabolism to support cell growth was the so-called “Warburg effect”, reporting increased aerobic glycolysis in cancer cells with a corresponding increase in glucose uptake and lactate excretion [19,20].”
BackgroundPokhrel, R. H., Acharya, S., Ahn, J.-H., Gu, Y., Pandit, M., Kim, J., Park, Y., Kang, B., Ko, H., & Chang, J. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01420-9 · Cited by 99
“Background Tumor cells reprogram several metabolic pathways to meet their bioenergetics/biosynthetic demands [1]; this leads to changes in the tumor microenvironment (TME), affecting tumor-infiltrating cells [2].”
The alternative activity of nuclear PHGDH contributes to tumour growth under nutrient stress
Ma, C., Zheng, K., Jiang, K., Zhao, Q., Sha, N., Wang, W., Yan, M., Chen, T., Zhao, Y., & Jiang, Y. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00456-x · Cited by 97
Wen, Y., Xiong, X., Scott, T. L., Li, A. T., Wang, C., Weiss, H. L., Tan, L., Bradford, E. M., Fan, T. W. ‐., Chandel, N. S., et al. (2019) · Cell Death and Differentiation · doi:10.1038/s41418-018-0265-6 · Cited by 89
Self-citationControl of Oxidative Stress in Cancer Chemoresistance: Spotlight on Nrf2 Role
Barrera, G., Cucci, M. A., Grattarola, M., Dianzani, C., Muzio, G., & Pizzimenti, S. (2021) · Antioxidants · doi:10.3390/antiox10040510 · Cited by 103
“peroxisomes [12], altered metabolism, and hypoxia [13].”
BackgroundAcetyl-CoA synthetase 2(ACSS2): a review with a focus on metabolism and tumor development
Ling, R., Chen, G., Tang, X., Liu, N., Zhou, Y., & Chen, D. (2022) · Discover Oncology · doi:10.1007/s12672-022-00521-1 · Cited by 103
“Tumor metabolic reprogramming is controlled primarily by proteins that are involved in programming the hallmarks of cancer [19, 20].”
BackgroundLi, F., Liu, P., Mi, W., Li, L., Anderson, N. M., Lesner, N. P., Burrows, M., Plesset, J. B., Majer, A. D., Wang, G., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00671-3 · Cited by 100
“Defining metabolic interactions in liver tumor microenvironments provides enhanced understanding of disease progression and uncovers potential druggable dependencies for therapeutic intervention 5,49,50 .”
Hyperactivity of the transcription factor Nrf2 causes metabolic reprogramming in mouse esophagus
Fu, J., Xiong, Z., Huang, C. D., Li, J., Yang, W., Han, Y., Paiboonrungruan, C., Major, M. B., Chen, K., Kang, X., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005963 · Cited by 86
“In addition to the classical Warburg effect (aerobic glycolysis), hyperactive Nrf2, in fact, impacted oxidative phosphorylation in the esophagus as well, consistent with a current model of cancer metabolism (49).”
BackgroundThe emerging role of targeting cancer metabolism for cancer therapy
Farhadi, P., Yarani, R., Dokaneheifard, S., & Mansouri, K. (2020) · Tumor Biology · doi:10.1177/1010428320965284 · Cited by 91
“Cancer metabolism was first described by Otto Warburg in 1920s.(2,3) In cancer, the main pathway for glucose consumption is the transformation to lactate, to produce adenosine triphosphate (ATP) which is a much faster process than tricarboxylic acid cycle (TCA cycle) occurring in mitochondria.”
MethodLiquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives
Gatto, L., Franceschi, E., Nunno, V. D., Tosoni, A., Lodi, R., & Brandes, A. A. (2021) · The Oncologist · doi:10.1002/onco.13858 · Cited by 102
“In addition to circulating nucleic acid, analytical methods to capture the “metabolome,” the complex of tumor-associated proteins whose abundance drastically increases as a consequence of cancer-associated somatic mutations in specific enzymes, have also been revealed as a promising approach [77].”
MethodErdélyi, K., Ditrói, T., Johansson, H. J., Czikora, Á., Balog, N., Silwal‐Pandit, L., Ida, T., Olasz, J., Hajdú, D., Mátrai, Z., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2100050118 · Cited by 91
“The cellular reprogramming of metabolic pathways to aid tumor progression is a featured hallmark of most cancers (2, 3).”
BackgroundTidwell, T., Røsland, G. V., Tronstad, K. J., Søreide, K., & Hagland, H. R. (2022) · Cancer & Metabolism · doi:10.1186/s40170-022-00285-w · Cited by 98
“The complexity of cancer metabolism has become a major research area [4], contributing to many studies investigating the metabolic heterogeneity of tumors [5] mainly driven by perfusionlimited nutrient access [6].”
BackgroundBiochemistry and regulation of histone lysine l-lactylation
Sheng, X., Lin, H., Cole, P. A., & Zhao, Y. (2025) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-025-00876-7 · Cited by 124
Cell-Autonomous Metabolic Reprogramming in Hypoxia
Schito, L., & Rey, S. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.10.006 · Cited by 89
Metabolic Reprogramming of Non-Hodgkin's B-Cell Lymphomas and Potential Therapeutic Strategies
Ricci, J., & Chiche, J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00556 · Cited by 90
“Besides glucose, fatty acids and glutamine, other fuels such as lactate, acetate, the NEAA aspartate, asparagine and the EAA leucine, arginine and serine support cell growth in nutrientlimited environments [for details please refer to (20)].”
BackgroundCD36: an emerging therapeutic target for cancer and its molecular mechanisms
Ruan, C., Meng, Y., & Hu, S. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-03957-8 · Cited by 99
Molecular Mechanisms of Cutaneous Squamous Cell Carcinoma
Hedberg, M. L., Berry, C. T., Moshiri, A. S., Xiang, Y., Yeh, C. J., Atillasoy, C., Capell, B. C., & Seykora, J. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073478 · Cited by 108
“Metabolic reprogramming is a hallmark of many cancers, including skin cancer [206,207].”
BackgroundMechanisms of redox metabolism and cancer cell survival during extracellular matrix detachment
Hawk, M. A., & Schafer, Z. T. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.tm117.000260 · Cited by 86
“More salient for the topic at hand, glutamine metabolism is critically important for the production of glutathione and NADPH which both function to detoxify ROS in a fashion that is required for cancer cell survival (19,37-44).”
BackgroundHigh Expression of Glycolytic Genes in Cirrhosis Correlates With the Risk of Developing Liver Cancer
Lee, N. C. W., Carella, M. A., Papa, S., & Bubici, C. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00138 · Cited by 89
“Indeed, it has been suggested that in cancer cells the production of ROS by complex I, II, and III of the electron transport chain contributes to DNA damage and is required for cancer cell survival, Kras-induced cellular transformation and cancer metastasis (Weinberg et al., 2010; Takahashi et al., 2018; Frontiers in…”
BackgroundInfluentialZhou, Y., Wang, Q., Zheng, X., 邓海峰, Xu, B., Zhou, Y., Liu, J., Liu, Y., Kong, X., Shi, Y., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-022-04503-7 · Cited by 96
“Dysfunction of energy metabolism is thought to be a distinct feature of cancer [4].”
BackgroundGlycerol 3-phosphate dehydrogenases (1 and 2) in cancer and other diseases
Oh, S., Mai, X. L., Kim, J., de Guzman, A. C. V., Lee, J. Y., & Park, S. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01222-1 · Cited by 98
“Well-known oncogenes or tumor suppressor genes, such as KRAS , P53 , MYC , and EGFR , have profound effects on metabolism 122 – 124 .”
BackgroundLipid droplets, potential biomarker and metabolic target in glioblastoma
Guo, D. (2017) · Internal Medicine Review · doi:10.18103/imr.v3i5.443 · Cited by 95
“Recent progress in the understanding of cancer biology has revealed that metabolism reprogramming is a new hallmark of malignancies (44-47).”
BackgroundHe, Y., Chen, X., Yu, Y. H., Li, J., Hu, Q., Xue, C., Chen, J., Shen, S., Luo, Y., Ren, F., et al. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22799 · Cited by 87
“During aerobic glycolysis, lactate dehydrogenase-A (LDHA) preferentially metabolizes pyruvate to lactate.(5) Persistent aerobic glycolysis is a key metabolic dependency in tumorigenesis.”
BackgroundZhang, W. C., Wells, J. M., Chow, K.-H., Huang, H., Yuan, M., Saxena, T., Melnick, M. A., Politi, K. A., Asara, J. M., Costa, D. B., et al. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0052-9 · Cited by 86
de Alteriis, E., Cartenì, F., Parascandola, P., Serpa, J., & Mazzoleni, S. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1442622 · Cited by 80
“It has been shown that, besides glucose, a panoply of fuels (glutamine, fatty acids and lactate) can be utilized by tumour cells, thus contributing to their metabolic function and plasticity [40]).”
BackgroundWei, Z., Jia, J., Heng, G., Xu, H., Shan, J., Wang, G., Liu, C., Xia, J., Zhou, H., Wu, M. C., et al. (2019) · Hepatology · doi:10.1002/hep.30622 · Cited by 86
“Metabolic reprogramming has been identified as a hallmark of cancer and responsible for tumor progression.(14) Recent studies focus on metabolic reprogramming following malignant transformation of normal cells(15) or during tumor metastasis.”
BackgroundKim, J. A., Wales, D. J., & Yang, G. (2020) · Progress in Biomedical Engineering · doi:10.1088/2516-1091/abaaa3 · Cited by 95
Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies
Reyes‐Castellanos, G., Masoud, R., & Carrier, A. (2020) · Biomedicines · doi:10.3390/biomedicines8080270 · Cited by 88
“In contrast, cancer cells are able to fulfill their anabolic needs with minimal dependence on extrinsic stimuli by growth factors [16], through deregulation of pathways related to energy production and biosynthesis (Figure 1).”
BackgroundRao, Y., Gammon, S. T., Zacharias, N. M., Liu, T. W. B., Salzillo, T. C., Xi, Y., Wang, J., Bhattacharya, P. K., & Piwnica-Worms, D. R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003537117 · Cited by 85
Repurposing Medications for Treatment of Pulmonary Arterial Hypertension: What's Old Is New Again
Prins, K. W., Thenappan, T., Weir, Ε. K., Kalra, R., PRITZKER, M. R., & Archer, S. L. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.011343 · Cited by 80
Targeting Metabolic Reprogramming in Acute Myeloid Leukemia
Castro, I., Sampaio‐Marques, B., & Ludovico, P. (2019) · Cells · doi:10.3390/cells8090967 · Cited by 92
“Apparently, this process might support lipogenesis in tumor cells [21].”
BackgroundWalsby-Tickle, J., Gannon, J. M., Hvinden, I. C., Bardella, C., Abboud, M. I., Nazeer, A., Hauton, D., Pires, E., Cadoux-Hudson, T. A. D., Schofield, C. J., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-0957-6 · Cited by 85
The mixed blessing of AMPK signaling in Cancer treatments
Sadria, M., Seo, D., & Layton, A. T. (2022) · BMC Cancer · doi:10.1186/s12885-022-09211-1 · Cited by 87
“To support their growth and proliferation, cancer cells reprogram their metabolism to promote nutrient uptake [1].”
BackgroundZhou, Q., Lin, W., Wang, C., Sun, F., Ju, S., Chen, Q., Wang, Y., Chen, Y., Li, H., Wang, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30559-2 · Cited by 78
“Our conclusion is supported by the following lines of evidence: (1) inactivation of the entire neddylation or of CRL3 in particular via pharmacological or genetic approaches causes ASCT2 accumulation; (2) SPOP binds to ASCT2 under physiological conditions, and the SPOP-ASCT2 binding is dependent on the evolutionarily…”
BackgroundResultFang, Z., Wang, C., Yang, J., Song, Z., Xie, C., Ji, Y., Wang, Z., Du, X., Zheng, Q., Chen, C., et al. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01501-4 · Cited by 95
Achreja, A., Zhao, H., Yang, L., Yun, T. H., Marini, J., & Nagrath, D. (2017) · Metabolic Engineering · doi:10.1016/j.ymben.2017.01.001 · Cited by 78
Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies
Pizzimenti, S., Ribero, S., Cucci, M. A., Grattarola, M., Monge, C., Dianzani, C., Barrera, G., & Muzio, G. (2021) · Antioxidants · doi:10.3390/antiox10121942 · Cited by 79
“Another important source of ROS in the skin is melanin synthesis, which involves oxidative reactions, with the production of superoxide anion and hydrogen peroxide (H2O2) at various steps of the synthetic melanin pathway [88].”
BackgroundThe Heterogeneity of Lipid Metabolism in Cancer
Park, J. K., Coffey, N. J., Limoges, A., & Le, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77736-8_3 · Cited by 82
LONP1 and ClpP cooperatively regulate mitochondrial proteostasis for cancer cell survival
Lee, Y. G., Kim, H. W., Nam, Y., Shin, K. J., Lee, Y. J., Park, D. H., Rhee, H., Seo, J. K., & Chae, Y. C. (2021) · Oncogenesis · doi:10.1038/s41389-021-00306-1 · Cited by 88
The evolution and ecology of benign tumors
Boutry, J., Tissot, S., Újvári, B., Capp, J., Giraudeau, M., Nedelcu, A. M., & Thomas, F. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188643 · Cited by 113
“It is well established that the metabolism of cancer cells is different from that of healthy cells[59].”
BackgroundMYCN-driven fatty acid uptake is a metabolic vulnerability in neuroblastoma
Tao, L., Mohammad, M. A., Milazzo, G., Moreno‐Smith, M., Patel, T. D., Zorman, B., Badachhape, A., Hernandez, B. E., Wolf, A. B., Zeng, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31331-2 · Cited by 83
Pancreatic tumors exhibit myeloid-driven amino acid stress and upregulate arginine biosynthesis
Saab, J. J. A., Dzierozynski, L. N., Jonker, P. B., AminiTabrizi, R., Shah, H., Menjivar, R. E., Scott, A. J., Nwosu, Z. C., Zhu, Z., Chen, R. N., et al. (2023) · eLife · doi:10.7554/elife.81289 · Cited by 88
“Altered cellular metabolism is common in cancers (DeBerardinis and Chandel, 2016) and enables many pathological features of tumors (Faubert et al., 2020; Vander Heiden and DeBerardinis, 2017).”
BackgroundHlouschek, J., Hansel, C., Jendrossek, V., & Matschke, J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00170 · Cited by 91
“Moreover, a progressive upregulation of cellular antioxidant systems has been associated with malignant progression (31), suggesting a broader relevance of the above findings for understanding tumor progression and clonal evolution of therapy-resistant cells in tumors with heterogeneous environments.”
BackgroundRole of Akt Activation in PARP Inhibitor Resistance in Cancer
Gallyas, F., Sümegi, B., & Szabó, C. (2020) · Cancers · doi:10.3390/cancers12030532 · Cited by 81
“Accordingly, increased anaerobic glycolysis, modified oxidative phosphorylation, and mitochondrial remodeling are hallmarks of cancer cells’ phenotype [120].”
BackgroundXu, J., Yu, T., Zois, C. E., Cheng, J., Tang, Y., Harris, A. L., & Huang, W. E. (2021) · Cancers · doi:10.3390/cancers13071718 · Cited by 82
“In particular, how cancer cells reprogram their metabolism and interact with other biological processes, which mechanisms and functions of nutrient acquisition in cancer cells are achieved, and what targeted pathways in metabolism can be engaged to selective development of inhibitors during therapeutic evaluation [3].”
BackgroundSadeghi, M., Kashanian, S., Naghib, S. M., & Arkan, E. (2022) · Scientific Reports · doi:10.1038/s41598-022-07230-3 · Cited by 78
“Schematic presentation of fabrication procedure of aptasensor for detecting HER2-ECD oncomarker: (1) the synthesis of rGONs, (2) the process of formation of Rh-NPs, (3) the immobilization of aptamer strands, and (4) the HER2-ECD detection using the proposed aptasensor.”
MethodHigh-Dose Vitamin C for Cancer Therapy
Mussa, A., Idris, R. A. M., Ahmed, N., Ahmad, S., Murtadha, A. H., Din, T. A. D. A. T., Yean, C. Y., Rahman, W. F. W. A., Lazim, N. M., Uskoković, V., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15060711 · Cited by 91
“Initially, by producing hydroxyl radical (OH•) through the Fenton reaction, extracellular H2O2 may effectively kill cancer cells [102].”
BackgroundWang, M., Chen, X., Tan, P., Wang, Y., Pan, X., Lin, T., Jiang, Y., Wang, B., Xu, H., Wang, Y., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.08.010 · Cited by 84
Hosseini, M., Rezvani, H. R., Aroua, N., Bosc, C., Farge, T., Saland, E., Guyonnet‐Dupérat, V., Zaghdoudi, S., Jarrou, L., Larrue, C., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0515 · Cited by 84
The role of glutamate receptors in the regulation of the tumor microenvironment
Koda, S., Hu, J., Ju, X., Sun, G., Shao, S., Tang, R., Zheng, K., & Yan, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1123841 · Cited by 93
“Frontiers in Immunology 02 Compared to normal cells, cancer cells are characterized by the rapid proliferation of cells, followed by a highly active metabolism (7).”
BackgroundMetabolic determinants of tumour initiation
Brunner, J. S., & Finley, L. W. S. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00773-5 · Cited by 87
Deoxyribonucleotide Triphosphate Metabolism in Cancer and Metabolic Disease
Buj, R., & Aird, K. M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00177 · Cited by 76
“Other successful chemotherapeutic regimens include methotrexate, which reduces substrates for purine and pyrimidine biosynthesis (157).”
BackgroundMetabolic Alterations in Cancer and Their Potential as Therapeutic Targets
Weyandt, J. D., Thompson, C. B., Giaccia, A. J., & Rathmell, W. K. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175561 · Cited by 85
Pacella, I., & Piconese, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01889 · Cited by 83
“Since then, researchers have accumulated a huge amount of information about the numerous metabolic routes that, together with glycolysis, characterize tumor cell proliferation and survival (104, 105).”
BackgroundYim, A., Koti, P. S., Bonnard, A., Marchianò, F., Dürrbaum, M., García-Pérez, C., Villaveces, J. M., Gamal, S., Cardone, G., Perocchi, F., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1128 · Cited by 77
Mutant p53 as a Regulator and Target of Autophagy
Shi, Y., Norberg, E., & Vakifahmetoglu-Norberg, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.607149 · Cited by 86
Bonet‐Aleta, J., Sancho‐Albero, M., Calzada-Funes, J., Irusta, S., Martín‐Duque, P., Hueso, J. L., & Santamaría, J. (2022) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2022.03.036 · Cited by 76
Metabolic rewiring in mutant Kras lung cancer
Kerr, E. M., & Martins, C. P. (2017) · FEBS Journal · doi:10.1111/febs.14125 · Cited by 84
Metabolism in cancer metastasis: bioenergetics, biosynthesis, and beyond
Teoh, S. T., & Lunt, S. Y. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1406 · Cited by 87
“Anti-angiogenic therapy induces an adaptive shift to increased dependence on fatty acid biosynthesis, which may accelerate tumor regrowth and metastasis after treatment withdrawal; this could be prevented by inhibiting FASN.227 However, metastasizing cells have also been observed to downregulate fatty acid synthesis,…”
Background
Metadata
- Authors
- DeBerardinis, R. J., & Chandel, N. S.
- Affiliations
- Children's Medical Center (US)
- Northwestern University (US)
- Corresponding author
- DeBerardinis, Ralph J.
- Chandel, Navdeep S.
- Venue
- Science Advances
- Published
- 2016-05-06
- Volume
- 2
- Issue
- 5
- Pages
- e1600200-e1600200
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC4928883
- OpenAlex
- W2395626624
- Semantic Scholar
- bebecd5b21653ab07940aa17ec319c54e710f9dc
- Cited by
- 3,013
- References
- 204
- Citations by year
- 2026: 271 · 2025: 296 · 2024: 326 · 2023: 359 · 2022: 427 · 2021: 447 · 2020: 340 · 2019: 257 · 2018: 166 · 2017: 109 · 2016: 12
- FWCI
- 16.51
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (ID0E1EAG7327, R01 CA123067)
- National Cancer Institute (ID0EAMAG7328, 5R01CA157996)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- cancer metabolism, metabolic reprogramming, tumor bioenergetics, redox metabolism, nutrient acquisition, carcinogenesis, metastasis, cancer therapy
- MeSH terms
- Animals, Energy Metabolism, Humans, Mitochondria, Neoplasms, Oxidation-Reduction, Signal Transduction, Reactive Oxygen Species, Macromolecular Substances, Metabolic Networks and Pathways, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.